TEV-749の長期効用統合失調症注射の第3相SOLARIS試験では,注射後の妄想/鎮静症候群は認められず,改善が顕著でした. Teva Pharmaceuticals' Phase 3 SOLARIS trial for TEV-749 long-acting schizophrenia injection shows significant improvements and no post-injection delirium/sedation syndrome.
テバ製薬は,統合失調症の長期効力薬であるTEV-749の SOLARIS 試験第3相の陽性結果を発表しました. Teva Pharmaceuticals announced positive results from its Phase 3 SOLARIS trial for TEV-749, a long-acting injection for schizophrenia. プラセボと比較して,陽性・陰性症候群スケール (PANSS) と重要な二次測定値で有意な改善を示した. The study met its primary endpoint, showing significant improvements in the Positive and Negative Syndrome Scale (PANSS) and key secondary measures compared to placebo. 重要なことに,注射後の妄想症/鎮静症候群の症例は認められず,既存の治療法で大きな懸念事項となった. Importantly, there were no cases of post-injection delirium/sedation syndrome, addressing a major concern with existing treatments. これは長期効力を有する治療を必要とする患者にとって新しい選択肢となるかもしれません This could provide a new option for patients needing long-acting therapy.